Please login to the form below

Not currently logged in

Pfizer names new emerging markets chief

Pfizer has appointed David Simmons to serve as its new head of emerging markets, succeeding Jean-Michel Halfon
Pfizer has appointed David Simmons to serve as its new head of emerging markets, succeeding Jean-Michel Halfon, according to a report from Bloomberg attributed to a company spokesperson. Halfon's retirement, which is effective in the first quarter of 2011, was announced internally a week ago but was not made public at the time. 

Simmons will continue as president and general manager of the Established Products Business Unit, a role in which he oversees drugs with expired patents as well as generics made by Pfizer's Greenstone unit, and will add Halfon's emerging markets duties to his existing ones. 

The Established Products Business Unit was created about two years ago under Simmons' leadership. Simmons has been working for Pfizer for 12 years in regions including the UK, Greece, Canada and the US.  He serves as the executive sponsor of the Pfizer African American Leadership Network and as a member of the US-India Business Council. Earlier in his career, he was an executive in the steel industry.

Halfon has been with Pfizer since 1997, serving in roles including head of Pfizer's Canada operations before taking over the emerging markets business. 

Simmons' new role comes amidst much larger management changes for Pfizer, which announced this week that Jeffrey Kindler was stepping down as CEO after four and a half years and would be replaced by Ian Reed, who has been in charge of worldwide pharma operations at the company since 2006.

9th December 2010


Featured jobs

Subscribe to our email news alerts


Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...